A team of seasoned experts and visionaries
LimmaTech is led by a dynamic management team with extensive expertise in vaccine development. Their proven track records and commitment to innovation drive our mission to address emerging antimicrobial resistance and global medical needs.

LimmaTech Franz-Werner Haas

Franz joined LimmaTech as Chief Executive Officer in August 2023. He has held roles of increasing complexity and responsibility in the pharmaceutical industry for more than 20 years. Most recently, he was the CEO at NASDAQ-listed CureVac SE following his tenures as Chief Corporate Officer and Chief Operating Officer. Before, Franz held the position of Vice President of Operations and Chief Compliance Officer of SYGNIS Pharma AG, where he was responsible for M&A, capital market transactions and corporate development. In the past, he held several management positions in the life sciences industry, including Vice President and General Counsel of LION Bioscience and General Counsel of Sirona Dental Systems. He holds a Doctor of Laws (LL.D.) degree and studied at the University of Saarbruecken, the Catholic University of Leuven, and the University of Edinburgh.


As Chief Operating Officer, Patricia is responsible for LimmaTech’s vaccine clinical programs. She joined GlycoVaxyn in 2014 in the Clinical Department and became part of LimmaTech’s Executive Management team in 2019 as Vice President of Clinical and Regulatory Affairs and later as Managing Director. Prior to GlycoVaxyn, Patricia held various roles in clinical research in several biotech companies and CROs. In her over 15 years of industrial experience, she has acquired significant expertise in diverse vaccine and therapeutic clinical indications and has overseen studies ranging from Phase I to Phase IV. Patricia has a degree in Biochemistry from the National University of Cordoba, Argentina. After relocating to Switzerland, she received her PhD in Natural Science from the University of Zürich.


As Chief Scientific Officer, Michael is responsible for LimmaTech’s scientific development, focusing on pipeline expansion and operational R&D performance. Michael has a PhD in Biochemistry from the Swiss Federal Institute of Technology, Zurich (ETH Zurich) and has developed broad experience in the biotech industry. After university, he joined GlycoVaxyn to develop the company’s bioconjugation vaccine platform. As VP of Research and IP, he was responsible for platform science innovation and the collaboration with GSK that culminated in GlycoVaxyn’s acquisition by GlaxoSmithKline in February 2015. After that, Michael became a co-founder of LimmaTech, and soon took the role of VP of Business Strategy and IP to drive LimmaTech’s proprietary business, marking his journey into therapeutics. With the successful spin-out of the therapeutics assets into the newly formed company GlycoEra AG in January 2021, as CSO of the company, he moved back to his true scientific passion, developing innovative vaccines.


As Chief Financial Officer, Paul is responsible for finance, administration, IT and human resources at LimmaTech. Most recently, he was CFO of GlycoVaxyn at the time of its acquisition by GlaxoSmithKline in February 2015. Previously, Paul was the Chief Financial Officer of Source Capital, a FINMA-regulated algorithmic trading firm in Switzerland from 2012 to 2014. He was Managing Director of Investors Guaranty, a boutique private equity and venture capital firm, where he managed the financial and corporate development activities and served as a board member for the group’s portfolio companies from 2001 to 2012. Prior to 2001, he worked for SEI Investments in the United States and Switzerland in various corporate finance positions focusing on the company’s new ventures. Paul holds a B.S. in finance from LaSalle University and an MBA from Villanova University.